COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.

COVID-19 vaccination around ICI therapy is linked to modest, short-term reductions in all-cause mortality among cancer patients, with no long-term survival benefit observed.

• Why it matters: Understanding how COVID-19 vaccines interact with immune checkpoint inhibitors is crucial for optimizing cancer treatment and vaccination strategies, especially given limited population-level evidence.
• What they did: Analyzing data from 95,015 adults in France who initiated ICI therapy between December 2020 and March 2023, researchers assessed vaccination timing relative to ICI start using advanced statistical methods.
• The result: Early post-vaccination periods showed reduced mortality risk (up to 14%) that dissipated after 12 months, indicating transient effects likely driven by healthy-vaccinee bias rather than specific vaccine benefits.